NEW YORK – GeneDx said Tuesday that it has teamed up with Komodo Health, a healthcare informatics technology company, to increase access to GeneDx's rare disease dataset.
Under the strategic partnership, the deidentified dataset, which includes more than 500,000 exomes, will be made available to biopharmaceutical companies through Komodo Health's MapEnhance offering.
"Combining the power of GeneDx's genetic intelligence with Komodo's comprehensive and longitudinal view into patient journeys is going to be a massive accelerant for companies looking to advance precision medicine and help to pave the way for more personalized treatments for patients," said Brad Kelley, general manager of MapEnhance at Komodo Health, in a statement.
MapEnhance integrates different types of patient data including lab tests, genomic data, EMR data, race and ethnicity, and social determinants of health.